Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids

Archives of Internal Medicine

Volumn 163, Issue 15, 2003, Pages 1801-1807

  Van der Linden, Paul D ^a,b   Sturkenboom, Miriam C J M ^a   Herings, Ron M C ^b   Leufkens, Hubert M G ^b   Rowlands, Sam ^c   Stricker, Bruno H Ch ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Epidemiol/Pharmacol Info Core   (United Kingdom)

^d Drug Safety Unit   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CORTICOSTEROID; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACHILLES TENDON RUPTURE; ADULT; AGED; AGING; ANAMNESIS; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR;

4-QUINOLONES; ACHILLES TENDON; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; RUPTURE, SPONTANEOUS; STEROIDS;

EID: 0041653426     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.15.1801     Document Type: Article

References (38)

1. Bailey RR, Kirk JA, Peddie BA. Norfloxacin-induced rheumatic disease [letter]. N Z Med J. 1983;96:590.
2. Franck JL, Bouteiller G, Chagnaud P, Sapene M, Gautier D. Rupture des tendons d'achille chez deux adultes traites par pefloxacine dont un cas bilateral [letter]. Rev Rhum Mal Osteoartic. 1991;58:904.
3. Jorgensen C, Anaya JM, Didry C, et al. Arthropathies et tendinopathie achilleenne induites par la pefloxacine: a propos d'une observation. Rev Rhum Mal Osteoartic. 1991;58:623-625.
4. McEwan SR, Davey PG. Ciprofloxacin and tenosynovitis [letter]. Lancet. 1988;2:900.
5. Szarfman A, Chen M, Blum MD. More on fluoroquinolone antibiotics and tendon rupture [letter]. N Engl J Med. 1995;332:193.
6. Pierfitte C, Royer RJ. Tendon disorders with fluoroquinolones. Therapie. 1996;51:419-420.
7. Ribard P, Audisio F, Kahn MF, et al. Seven Achilles tendinitis including 3 complicated by rupture during fluoroquinolone therapy. J Rheumatol. 1992;19:1479-1481.
8. Zabraniecki L, Negrier I, Vergne P, et al. Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol. 1996;23:516-520.
9. van der Linden PD, Sturkenboom MCJM, Herings RMC, Leufkens HGM, Stricker BHC. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ. 2002;324:1306-1307.
10. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991;324:384-394.
11. Lietman PS. Fluoroquinolone toxicities: an update. Drugs. 1995;49(suppl 2):159-163.
12. Moellering RC Jr. The place of quinolones in everyday clinical practice. Chemotherapy. 1996;42(suppl 1):54-61.
13. Hooper DC. Expanding uses of fluoroquinolones: opportunities and challenges. Ann Intern Med. 1998;129:908-910.
14. Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends. Spring 1997:36-40.
15. Jick H. A database worth saving. Lancet. 1997;350:1045-1046.
16. Van der Linden PD, Van Puijenbroek EP, Feenstra J, et al. Tendon disorders attributed to fluoroquinolones: a study of spontaneous reports in the period 1988 to 1998. Arthritis Rheum. 2001;45:235-239.
17. World Health Organization. Anatomical Therapeutic Classification (ATC) Index: Including Defined Daily Doses (DDD) for Plain Substances. Oslo, Norway: World Health Organization; 1992.
18. Cronin ME. Musculoskeletal manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am. 1988;14:99-116.
19. Donck JB, Segaert MF, Vanrenterghem YF. Fluoroquinolones and Achilles tendinopathy in renal transplant recipients. Transplantation. 1994;58:736-737.
20. Grant WP, Sullivan R, Sonenshine DE, et al. Electron microscopic investigation of the effects of diabetes mellitus on the Achilles tendon. J Foot Ankle Surg. 1997;36:272-278.
21. Jones N, Kjellstrand CM. Spontaneous tendon ruptures in patients on chronic dialysis. Am J Kidney Dis. 1996;28:861-866.
22. Lauzon C, Carette S, Mathon G. Multiple tendon rupture at unusual sites in rheumatoid arthritis. J Rheumatol. 1987;14:369-371.
23. Mahler F, Fritschy D. Partial and complete ruptures of the Achilles tendon and local corticosteroid injections. Br J Sports Med. 1992;26:7-14.
24. Matsumoto K, Hukuda S, Nishioka J, Asajima S. Rupture of the Achilles tendon in rheumatoid arthritis with histologic evidence of enthesitis: a case report. Clin Orthop. July 1992:235-240.
25. Newnham DM, Douglas JG, Legge JS, Friend JA. Achilles tendon rupture: an underrated complication of corticosteroid treatment. Thorax. 1991;46:853-854.
26. Waterston SW, Maffulli N, Ewen SW. Subcutaneous rupture of the Achilles tendon: basic science and some aspects of clinical practice. Br J Sports Med. 1997;31:285-298.
27. Leppilahti J, Orava S. Total Achilles tendon rupture: a review. Sports Med. 1998;25:79-100.
28. Hayem G, Carbon C. A reappraisal of quinolone tolerability: the experience of their musculoskeletal adverse effects. Drug Saf. 1995;13:338-342.
29. Kahn MF, Hayem G. Tendons and fluoroquinolones: unresolved issues. Rev Rhum Engl Ed. 1997;64:437-439.
30. van der Linden PD, van de Lei J, Nab HW, Knol A, Stricker BHC. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol. 1999;48:433-437.
31. Kashida Y, Kato M. Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds. Antimicrob Agents Chemother. 1997;41:2389-2393.
32. Moller A, Astron M, Westlin N. Increasing incidence of Achilles tendon rupture. Acta Orthop Scand. 1996;67:479-481.
33. Leppllahti J, Puranen J, Orava S. Incidence of Achilles tendon rupture. Acta Orthop Scand. 1996;67:277-279.
34. Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol. 1996;41:277-284.
35. Jozsa L, Kvist M, Balint BJ, et al. The role of recreational sport activity in Achilles tendon rupture: a clinical, pathoanatomical, and sociological study of 292 cases. Am J Sports Med. 1989;17:338-343.
36. Kato M, Takada S, Kashida Y, Nomura M. Histological examination on Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats. Toxicol Pathol. 1995;23:385-392.
37. Simonin MA, Gegout-Pottie P, Minn A, Gillet P, Netter P, Terlain B. Pefloxacin-induced achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen. Antimicrob Agents Chemother. 2000;44:867-872.
38. Shakibaei M, Pfister K, Schwabe R, Vormann J, Stahlmann R. Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet. Antimicrob Agents Chemother. 2000;44:261-266.